Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record.

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study

Open access
Carlsen, Esben Andreas, Fazio, Nicola, Granberg, Dan, Grozinsky-Glasberg, Simona, Ahmadzadehfar, Hojjat, Grana, Chiara Maria, Zandee, Wouter T, Cwikla, Jaroslaw, Walter, Martin A, Oturai, Peter Sandor, Rinke, Anja, Weaver, Andrew, Frilling, Andrea, Gritti, Sara, Arveschoug, Anne Kirstine, Meirovitz, Amichay, Knigge, Ulrich, Sorbye, Halfdan · 2019 · Endocrine-Related Cancer

Abstract

Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine tumors grade 1–2 (G1–G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN G3) is largely unknown. We therefore aimed to assess the benefits and side effects of PRRT in patients with GEP NEN G3. We performed a retrospective cohort study at 12 centers to assess the efficacy and toxicity of PRRT in patients with GEP NEN G3. Outcomes were response rate, disease control rate, progression-free survival (PFS), overall survival (OS) and toxicity. We included 149 patients (primary tumor: pancreatic n = 89, gastrointestinal n = 34, unknown n = 26). PRRT was first-line (n = 30), second-line (n = 62) or later-line treatment (n = 57). Of 114 patients evaluated, 1% had complete response, 41% partial response, 38% stable disease and 20% progressive disease. Of 104 patients with documented progressive disease before PRRT, disease control rate was 69%. The total cohort had median PFS of 14 months and OS of 29 months. Ki-67 21–54% (n = 125) vs Ki-67 ≥55% (n = 23): PFS 16 vs 6 months (P < 0.001) and OS 31 vs 9 months (P < 0.001). Well (n = 60) vs poorly differentiated NEN (n = 62): PFS 19 vs 8 months (P < 0.001) and OS 44 vs 19 months (P < 0.001). Grade 3–4 hematological or renal toxicity occurred in 17% of patients. This large multicenter cohort of patients with GEP NEN G3 treated with PRRT demonstrates promising response rates, disease control rates, PFS and OS as well as toxicity in patients with mainly progressive disease. Based on these results, PRRT may be considered for patients with GEP NEN G3.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/erc-18-0424

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 159

Metadata

Authors
Carlsen, E. A., Fazio, N., Granberg, D., Grozinsky-Glasberg, S., Ahmadzadehfar, H., Grana, C. M., Zandee, W. T., Cwikla, J., Walter, M. A., Oturai, P. S., Rinke, A., Weaver, A., Frilling, A., Gritti, S., Arveschoug, A. K., Meirovitz, A., Knigge, U., & Sorbye, H.
Venue
Endocrine-Related Cancer
Published
2019-02
Volume
26
Issue
2
Pages
227-239
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W2905501684
Cited by
159
References
0
FWCI
10.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. https://app.cochat.ai/papers/10.1530/erc-18-0424
The paper
Carlsen, E. A., Fazio, N., Granberg, D., Grozinsky-Glasberg, S., Ahmadzadehfar, H., Grana, C. M., Zandee, W. T., Cwikla, J., Walter, M. A., Oturai, P. S., Rinke, A., Weaver, A., Frilling, A., Gritti, S., Arveschoug, A. K., Meirovitz, A., Knigge, U., & Sorbye, H. (2019). Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocrine-Related Cancer. https://doi.org/10.1530/erc-18-0424

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.